Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis
Surgically resected MIBC was associated with a substantial economic burden with disease recurrence experiencing higher HCRU and health care costs. These findings underscore the need for novel and effective therapies that can prevent or delay disease recurrence for patients with MIBC.
Authors
- Aljosja Rogiers (ORCID: https://orcid.org/0000-0002-3807-9696)
- Anya Jiang
- Patrick Squires (ORCID: https://orcid.org/0009-0003-6819-5764)
- Erin Cook (ORCID: https://orcid.org/0000-0001-9737-9130)
- Shravanthi M. Seshasayee (ORCID: https://orcid.org/0000-0002-1692-7121)
- Ronac Mamtani (ORCID: https://orcid.org/0000-0002-8267-5356)
- Adina Zhang (ORCID: https://orcid.org/0000-0001-7451-7756)
- Yan Song (ORCID: https://orcid.org/0000-0001-6530-4927)
- Haojie Li (ORCID: https://orcid.org/0000-0001-6233-8603)
- Ching-Yu Wang
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Penn Presbyterian Medical Center (US)
- Hospital of the University of Pennsylvania (US)
- UPMC Presbyterian (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-09-17
- DOI
- https://doi.org/10.18553/jmcp.2025.25106
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00